Given that anti-PD-1/L1 immunotherapy has been widely used in clinics, we speculate that the combination of HDAC inhibitors and targeting TET2 with anti-PD-L1 immunotherapy may be a new strategy for breast cancer patients who have low responsiveness to anti-PD-1/L1 immunotherapy. Here, PDCD1 is linked to breast cancer.